Findx
EnglishEnglish
Dansk Dansk

AZORA THERAPEUTICS, INC. AZR.US

Azora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered, colon-targeted therapies for immune-mediated inflammatory diseases. Following its 2026 merger and name change from Adial Pharmaceuticals, its core business centers on AT177, a fully synthetic aryl hydrocarbon receptor (AhR) agonist being advanced toward clinical proof-of-concept in ulcerative colitis, with planned expansion into Crohn's disease. The company no longer develops addiction- or alcohol-use disorder candidates, which were part of its legacy business.

AT177 is designed to restore mucosal immune homeostasis in the colon while minimizing systemic exposure to reduce potential side effects. It is a prodrug that delivers indirubin, the active AhR agonist derived from the botanical extract indigo naturalis. Azora is conducting IND-enabling studies for AT177, with an Investigational New Drug submission and commencement of a Phase 1a single- and multiple-ascending-dose clinical trial planned for the first half of 2027.

The company owns worldwide royalty-free rights to its AT177 technology, which emerged from Stanford University's SPARK translational medicine program. Azora's operations are based in Encino, California. It does not yet generate revenue from approved products and funds its development through capital raising, potential licensing, or strategic partnerships. Its research and manufacturing efforts include preclinical studies, GLP toxicology, GMP-compliant manufacturing, and regulatory submissions.

Healthcare · Biotechnology · Biotechnology · United States
Price development

Click to see warnings

‹
›
Years
Price: Financials: UnavailableEstimates: UnavailableScored as: Not scoredEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: Unavailable

Scoring profile

Effective scoring profile: Not scored

Score evidence

  • Findx has price history but not enough financial information to calculate the company scores.

Sources and adjustments

No derived inputs, proxies, or historical consensus fills affected these scores.

Quick facts

Blended P/E  :
N/A
Blended EPS  :
N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
N/A
Buyback Yield :
(Trailing 12 months)
N/A
Market Cap:USD 52.36 M
EUR 47.57 M

About Azora Therapeutics, Inc.

Basic company information

Company description

Azora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered, colon-targeted therapies for immune-mediated inflammatory diseases. Following its 2026 merger and name change from Adial Pharmaceuticals, its core business centers on AT177, a fully synthetic aryl hydrocarbon receptor (AhR) agonist being advanced toward clinical proof-of-concept in ulcerative colitis, with planned expansion into Crohn's disease.

The company no longer develops addiction- or alcohol-use disorder candidates, which were part of its legacy business. AT177 is designed to restore mucosal immune homeostasis in the colon while minimizing systemic exposure to reduce potential side effects.

It is a prodrug that delivers indirubin, the active AhR agonist derived from the botanical extract indigo naturalis. Azora is conducting IND-enabling studies for AT177, with an Investigational New Drug submission and commencement of a Phase 1a single- and multiple-ascending-dose clinical trial planned for the first half of 2027.

The company owns worldwide royalty-free rights to its AT177 technology, which emerged from Stanford University's SPARK translational medicine program. Azora's operations are based in Encino, California.

It does not yet generate revenue from approved products and funds its development through capital raising, potential licensing, or strategic partnerships. Its research and manufacturing efforts include preclinical studies, GLP toxicology, GMP-compliant manufacturing, and regulatory submissions.

More information

Log in to see details

Log in for full access

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.